Early detection of cisplatin ototoxicity using distortion product otoacoustic emission

ABSTRACT

The distortion product otoacoustic emission [DPOAE] can detect small changes in the cochlear status, due to its high sensitivity and specificity to the outer hair cells. This study was carried out on 25 patients receiving cisplatin [100 mg/m2 in 24 hr infusion every 21 days] for early detection of cisplatin ototoxicity in those patients who had normal hearing threshold by standard audiometric methods of evaluation [PTA, SDT, AR]. This work showed that there was a significant difference of the DOPAE at the high frequencies only, in patients that received only one cycle of cisplatin, compared with the control group. However, there was a significant difference in DOPAE in both the low and high frequencies in patients that received more than one cycle of cisplatin compared to the control group